GF-CART01 / GenomeFrontier Therap - LARVOL DELTA

Long-term Study to Evaluate Safety and Persistence of GF-CART01 (clinicaltrials.gov) - P=N/A | N=18 | Not yet recruiting | Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.

New trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Waldenstrom Macroglobulinemia

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects with Relapsed or Refractory B-Cell Hematological Malignancies (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.

CAR T-Cell Therapy • New P1 trial • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Waldenstrom Macroglobulinemia